Portal de Periódicos da CAPES

REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: Ambispective, multicenter clinical study. Results in the GLP1-experienced cohort

2024; Elsevier BV; Volume: 38; Issue: 12 Linguagem: Inglês

10.1016/j.jdiacomp.2024.108874

1873-460X

Jersy Cárdenas‐Salas, Roberto Miguel Sierra Poyatos, Bogdana Luiza Luca, Begoña Sánchez Lechuga, Naiara Modroño Móstoles, Teresa Montoya Álvarez, María de la Paz Gómez Montes, Jorge Gabriel Ruiz-Sánchez, Diego Meneses González, Raquel Sánchez-Lopez, C. Casès, Víctor Pérez de Arenaza Pozo, Clotilde Vázquez Martínez,

Pancreatic function and diabetes

To evaluate the efficacy of switching to once-weekly subcutaneous semaglutide in patients with type 2 diabetes mellitus (T2DM) who were previously treated with other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in a real-world setting in Spain.